Skip to main content
Premium Trial:

Request an Annual Quote

Coimbra Genomics Raises €2.4M

NEW YORK (GenomeWeb) – Digital health and precision medicine firm Coimbra Genomics announced today that it has secured a €2.4 million ($2.8 million) investment from Green Innovations.

The company said it would use the funds to accelerate the expansion of its Elsie platform — which is designed to allow doctors to use patients' genomic information to make prognostic and prescriptive decisions in the setting of a regular medical appointment — to international markets. According to Coimbra, the platform is currently used in Germany, Finland, Brazil, and Portugal.

"This is one more step in our commercial development path, with the ultimate objective of turning Elsie into the world-leading platform that carries reliable genomic information to the physician," Coimbra CEO Bruno Soares said in a statement.

Earlier this year, Coimbra announced that the Elsie platform would be used by a Portuguese hospital center to provide exome sequencing to its patients.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.